The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
|Videos|November 2, 2018
Dr. Salgia on FDA Approval of Lorlatinib in ALK+ NSCLC
Author(s)Ravi Salgia, MD, PhD
Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer.
Advertisement
Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non—small cell lung cancer (NSCLC).
Advertisement
Related to this article
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5